Search results for "monoclonal antibody"

showing 10 items of 356 documents

Combined heterologies for monoclonal antibody-based immunoanalysis of fluxapyroxad

2018

Nowadays, instrumental methodologies and rapid bioanalytical techniques complement each other for the analysis of toxic chemical compounds. Fluxapyroxad was commercialized a few years ago as a fungicide and today it is being used worldwide to control a variety of pests. In the present study, the development of monoclonal antibody-based immunochemical methods for the analysis of this chemical in food samples was evaluated for the first time. Novel haptens were synthesized and protein bioconjugates were prepared. High-affinity and specific monoclonal antibodies to fluxapyroxad were generated from two haptens with alternative linker tethering sites. Haptens with linker site heterology and a st…

Bioanalysismedicine.drug_classEnzyme-Linked Immunosorbent AssayFood ContaminationFluxapyroxadMonoclonal antibody01 natural sciencesBiochemistryAnalytical ChemistryMice0404 agricultural biotechnologyLimit of DetectionElectrochemistrymedicineIc50 valuesAnimalsEnvironmental ChemistryMoietySpectroscopyChromatographymedicine.diagnostic_testChemistry010401 analytical chemistryAntibodies Monoclonal04 agricultural and veterinary sciencesAmides040401 food scienceFungicides Industrial0104 chemical sciencesFruitImmunoassayPyrazolesHaptensHaptenLinkerThe Analyst
researchProduct

MANOTA: a promising bifunctional chelating agent for copper-64 immunoPET

2017

International audience; Improved bifunctional chelating agents (BFC) are required for copper-64 radiolabelling of monoclonal antibodies (mAbs) under mild conditions to yield stable, target-specific imaging agents. Four different bifunctional chelating agents (BFC) were evaluated for Fab (Fragment antigen binding) conjugation and radiolabelling with copper-64. Two DOTA- (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and two NOTA- (1,4,7-triazacyclononane-1,4,7-triacetic acid) derivatives bearing a p-benzyl-isothiocyanate group were conjugated to Fab-trastuzumab - which targets the HER2/neu receptor - and the average number of chelators attached ranged from 2.4 to 4.3 macrocycles …

BiodistributionImmunoconjugatesmedicine.drug_class[SDV.CAN]Life Sciences [q-bio]/CancerMonoclonal antibody030218 nuclear medicine & medical imaging[ SDV.CAN ] Life Sciences [q-bio]/CancerInorganic ChemistryHeterocyclic Compounds 1-RingImmunoglobulin Fab FragmentsMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCell Line TumormedicineAnimalsHumansDOTA[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyTissue DistributionChelationBifunctionalChelating AgentsRadiochemistryMammary Neoplasms ExperimentalTrastuzumabIn vitroImmunoconjugateCopper RadioisotopesBiochemistrychemistryPositron-Emission Tomography030220 oncology & carcinogenesis[SDV.IMM]Life Sciences [q-bio]/ImmunologyCopper-64
researchProduct

Separation and purification of no-carrier-added arsenic from bulk amounts of germanium for use in radiopharmaceutical labelling

2010

AbstractRadioarsenic labelled radiopharmaceuticals could add special features to molecular imaging with positron emission tomography (PET). For example the long physical half-lives of72As (T1/2=26 h) and74As (T1/2=17.8 d) in conjunction with their high positron branching rates of 88% and 29%, respectively, allow the investigation of slow physiological or metabolical processes, like the enrichment and biodistribution of monoclonal antibodies in tumour tissue or the characterization of stem cell trafficking. A method for separation and purification of no-carrier-added (nca) arsenic from irradiated metallic germanium targets based on distillation and anion exchange is developed. It finally con…

BiodistributionIon exchangeChemistrymedicine.drug_classSynthonRadiochemistrychemistry.chemical_elementGermaniumMonoclonal antibodyMetalLabellingvisual_artmedicinevisual_art.visual_art_mediumPhysical and Theoretical ChemistryArsenicNuclear chemistryRadiochimica Acta
researchProduct

Biosensor Analysis of β2-Glycoprotein I–Reactive Autoantibodies: Evidence for Isotype-Specific Binding and Differentiation of Pathogenic from Infecti…

2007

Abstract Background: For the laboratory diagnosis of the antiphospholipid syndrome (APS) we developed a biosensor with the ability to distinguish between disease-relevant anti-β2-glycoprotein I (β2GPI) autoantibodies (anti-β2GPI) and pathogen-specific β2GPI cross-reactive antibodies that occur transiently during infections. Methods: We used a surface plasmon resonance (SPR) biosensor device. For the detection of anti-β2GPI in serum samples, affinity-purified human β2GPI was covalently attached to a functionalized n-alkanethiol self-assembling monolayer on the biosensor chip. After verifying the specificity of the biosensor system with a panel of monoclonal antibodies to β2GPI, we analyzed s…

Biosensor devicemedicine.drug_classClinical BiochemistryEnzyme-Linked Immunosorbent AssayBiosensing TechniquesCross Reactionsmedicine.disease_causeMonoclonal antibodyAutoimmunityParvoviridae InfectionsAntiphospholipid syndromeParvovirus B19 HumanmedicineHumansLupus Erythematosus SystemicSyphilisTreponema pallidumAntigens ViralAutoantibodiesAntigens BacterialbiologyParvovirusBiochemistry (medical)AutoantibodySurface Plasmon ResonanceAntiphospholipid Syndromemedicine.diseasebiology.organism_classificationIsotypeMolecular biologyImmunoglobulin Isotypesbeta 2-Glycoprotein IImmunologyAntibodies Antiphospholipidbiology.proteinAntibodyProtein BindingClinical Chemistry
researchProduct

Functionally active complement proteins C6 and C7 detected in C6- and C7-deficient individuals

1991

SUMMARYTwo sensitive sandwich ELISAs based on monoclonal antibodies directed to native C6 and C7 allowed the detection and quantitation of these complement proteins in 20 out of 37 serum samples from individuals who had previously been classified as deficient in these proteins as assessed by immunochemical and/or functional assays. Furthermore, serum from four C6-deficient and one combined C6-/C7-deficient individual showed an increase in the terminal complement complex (TCC) and a decrease in native C6 and C7 after complement activation as assayed by specific ELISAs. Despite their (incomplete) deficiencies, these individuals therefore possess functionally active terminal complement protein…

Blood Bactericidal Activitymedicine.drug_classImmunoblottingImmunologyEnzyme-Linked Immunosorbent AssayBiologyMonoclonal antibodyComplement Hemolytic Activity AssaySpecimen Handling03 medical and health sciences0302 clinical medicineTerminal complement complexImmunopathologymedicineHumansImmunology and AllergyComplement ActivationVolume concentration030304 developmental biology0303 health sciencesTemperatureZymosanAntibodies MonoclonalComplement deficiencyComplement C9Serum samplesmedicine.diseaseMolecular biologyComplement C7Complement C63. Good healthComplement (complexity)Complement systemImmunologyElectrophoresis Polyacrylamide GelResearch Article030215 immunologyClinical and Experimental Immunology
researchProduct

Synthesis and Evaluation of a Novel Series of Pyrrolizine Derivatives as Dual Cyclooxygenase-1 and 5-Lipoxygenase Inhibitors

1997

The aim of our study was to investigate structure activity relationship following the replacement of the 6-phenyl substituent at the 6,7-diaryl-2,3-dihydropyrrolizine template by various heteroaromatic residues. In this context we developed a new, efficient, and highly sensitive test method for the screening of dual cyclooxygenase-1 (COX-1) and 5-lipoxygenase (5-LOX) inhibitors. We used human platelets as a source of COX-1 and human PMNLs as a source of 5-LOX. Both cell types were isolated from the same volume of blood. PGE2 and LTB4 respectively were determined by highly selective and sensitive ELISA kits, using monoclonal antibodies. For a single determination at most 0.5 mL whole blood i…

Blood PlateletsMaleNeutrophilsmedicine.drug_classPharmaceutical ScienceContext (language use)Monoclonal antibodyChemical synthesisDrug DiscoverymedicineHumansStructure–activity relationshipCyclooxygenase InhibitorsPyrrolesLipoxygenase InhibitorsWhole bloodArachidonate 5-LipoxygenasebiologyChemistryMembrane ProteinsIn vitroIsoenzymesBiochemistryProstaglandin-Endoperoxide SynthasesEnzyme inhibitorArachidonate 5-lipoxygenaseCyclooxygenase 1biology.proteinFemaleArchiv der Pharmazie
researchProduct

Specific immunohistochemical identification of Candida albicans in paraffin-embedded tissue with a new monoclonal antibody (1B12).

1995

In invasive candidiasis, the identification of Candida organisms in tissue samples or in normally sterile fluids is essential for an accurate diagnosis. Species identification is an important clue for the source of infection and in epidemiological studies. In this article, the authors have tested the value of a new monoclonal antibody (1B12) to detect C albicans in culture by immunofluorescence, and in tissue samples by immunohistochemistry. MAb 1B12 was found to specifically recognize C albicans , does not cross-react with other Candida species or other structurally similar fungi, and is very sensitive and specific in paraffin-embedded tissue, having no reactivity in normal human tissues o…

Body fluidNecrosisParaffin Embeddingmedicine.diagnostic_testmedicine.drug_classAntibodies MonoclonalFluorescent Antibody TechniqueGeneral MedicineFungi imperfectiBiologyImmunofluorescenceMonoclonal antibodymedicine.diseasebiology.organism_classificationImmunohistochemistryMicrobiologyCandida albicansmedicineImmunohistochemistryHumansmedicine.symptomCandida albicansMycosisAmerican journal of clinical pathology
researchProduct

In Vitro Interactions of C-ANCA (Antibodies to Proteinase 3) with Human Endothelial Cells

1993

Several concepts concerning the pathogenicity of antineutrophil cytoplasmic antibodies (ANCA) exist, but till now only sparse data about ANCA-endothelial interactions are available. In this study we have investigated the expression of proteinase 3 (PR-3) in human umbilical endothelial cells (HEC) using purified anti-PR3 antibodies (C-ANCA) of patients with Wegener’s granulomatosis (WG) and monoclonal antibodies to PR-3 (human and murine) as probes. Performing cytoELISAs, laser scanning microscopy and Western blot we were able to show that treatment of HEC with IL-1-alpha led to an increased PR-3 expression in the cytoplasm and to a transient translocation into the EC-membrane. Representing …

C-ANCAmedicine.diagnostic_testmedicine.drug_classBiologyMonoclonal antibodyMolecular biologyIn vitroWestern blotProteinase 3Myeloblastinmedicinebiology.proteincardiovascular diseasesAntibodyAnti-neutrophil cytoplasmic antibody
researchProduct

Specific Targeting of Cytokine-Secreting Cells: A Bispecific Diabody Recognizing Human Interleukin-6 and CD3 Induces T Cell-Mediated Killing

1998

Cytokines have been implicated in the pathophysiology of many diseases. Although there have been many attempts to neutralize the activity of cytokines in vivo and in vitro, no strategies have been developed to specifically eliminate cells that overexpress cytokines. Considering the fact that cytokines in part remain cell associated on secretion, we have constructed a bispecific diabody consisting of a nonneutralizing scFv antibody recognizing human interleukin-6 (IL-6) and an scFv corresponding to the monoclonal antibody (mAb) OKT3, which recognizes and activates the human T cell receptor. Here we show that the diabody recognized both human IL-6 and human CD3. In the presence of human T cel…

CD3 Complexmedicine.drug_classCD3medicine.medical_treatmentT cellImmunologyReceptors Antigen T-CellMonoclonal antibodyCell LineAntigen-Antibody ReactionsVirologyAntibodies BispecificTumor Cells CulturedmedicineHumansSecretionCell DeathbiologyInterleukin-6ChemistryT-cell receptorAntibodies MonoclonalCell BiologyTransfectionMolecular biologyCytokinemedicine.anatomical_structurebiology.proteinCancer researchCytokinesAntibodyT-Lymphocytes CytotoxicJournal of Interferon & Cytokine Research
researchProduct

Catumaxomab: a bispecific trifunctional antibody.

2009

The trifunctional bispecific monoclonal antibody catumaxomab has two binding specificities directed at epithelial cell adhesion molecule (EpCAM) and the T-cell antigen CD3. With its Fc-fragment, catumaxomab additionally binds accessory cells such as dendritic cells, macrophages and natural killer cells. The trifunctional approach thus leads to unrestricted but specific killing of epithelial tumor cells by major histocompatibility complex without the need for preactivation or external costimulation. The tumor-associated antigen EpCAM is strongly expressed in carcinomas of various origins including colon, rectum, ovarian, gastric, esophagus, lung, pancreas, breast and head and neck. Expressio…

CD3CatumaxomabAntineoplastic AgentsMajor histocompatibility complexchemistry.chemical_compoundAntigenAntigens NeoplasmNeoplasmsAntibodies BispecificMedicineAnimalsHumansPharmacology (medical)PharmacologybiologyBispecific monoclonal antibodybusiness.industryDrug Administration RoutesModels ImmunologicalEpithelial cell adhesion moleculeGeneral MedicineTrifunctional antibodychemistrybiology.proteinCancer researchAntibodyDrug Screening Assays Antitumorbusinessmedicine.drugDrugs of today (Barcelona, Spain : 1998)
researchProduct